Translate Bio Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Translate Bio, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – TBIO
Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Translate Bio, Inc. (NASDAQ: TBIO) to Sanofi for $38.00 per share in cash is fair to Translate Bio shareholders.
- Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Translate Bio, Inc. (NASDAQ: TBIO) to Sanofi for $38.00 per share in cash is fair to Translate Bio shareholders.
- The investigation concerns whether Translate Bio and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Translate Bio shareholders; (2) determine whether Sanofi is underpaying for Translate Bio; and (3) disclose all material information necessary for Translate Bio shareholders to adequately assess and value the merger consideration.
- On behalf of Translate Bio shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
- Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.